(Q38059517)

28 August 2017

title

Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma (English)

1 reference

28 August 2017

1 reference

1 reference

Jon Arnason

1

1 reference

28 August 2017

David Avigan

series ordinal

2

1 reference

28 August 2017

publication date

1 October 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

4

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

1043-1051

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

28 August 2017

1 reference

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

NY-ESO-1 immunotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Immunodeficiency and immunotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Active immunotherapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Dendritic cells: development, function and potential use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Dendritic cell fusion vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Memory CD8 T-cell differentiation during viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.118

21 January 2018

Identifiers

DOI

10.2217/IMT.12.118

1 reference

28 August 2017

1 reference